Gilead Sciences Announces Second Quarter 2013 Financial Results

  Gilead Sciences Announces Second Quarter 2013 Financial Results

 - Total Revenues of $2.77 billion, Up 15 percent over Second Quarter 2012 -

  - Product Sales of $2.66 billion, Up 14 percent over Second Quarter 2012 -

Business Wire

FOSTER CITY, Calif. -- July 25, 2013

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations
for the quarter ended June 30, 2013. Total revenues for the second quarter of
2013 increased 15 percent to $2.77 billion, from $2.41 billion for the second
quarter of 2012. Product sales increased 14 percent to $2.66 billion for the
second quarter of 2013 compared to $2.32 billion for the second quarter of
2012. Net income for the second quarter of 2013 was $772.6 million, or $0.46
per diluted share compared to $711.6 million, or $0.46 per diluted share for
the second quarter of 2012. Non-GAAP net income for the second quarter of
2013, which excludes acquisition-related, restructuring and stock-based
compensation expenses, was $839.7 million, or $0.50 per diluted share compared
to $767.3 million, or $0.49 per diluted share for the second quarter of 2012.

                  Three Months Ended             Six Months Ended
                   June 30,                        June 30,
(In thousands,
except per share   2013           2012            2013           2012
amounts)
Product sales      $ 2,657,285     $ 2,321,240     $ 5,050,853     $ 4,529,582
Royalty,
contract and       110,109        83,946         248,176        158,053
other revenues
Total revenues     $ 2,767,394    $ 2,405,186    $ 5,299,029    $ 4,687,635
                                                                   
Net income
attributable to    $ 772,605       $ 711,564       $ 1,494,791     $ 1,153,520
Gilead
Non-GAAP net
income             $ 839,725       $ 767,277       $ 1,641,668     $ 1,471,666
attributable to
Gilead
                                                                   
Diluted EPS        $ 0.46          $ 0.46          $ 0.89          $ 0.74
Non-GAAP diluted   $ 0.50          $ 0.49          $ 0.98          $ 0.95
EPS
                                                                     

Product Sales

Product sales were driven primarily by growth in Gilead's antiviral franchise
during the second quarter of 2013. Contributing to the increase were sales of
Complera^®/Eviplera^® (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir
disoproxil fumarate 300 mg) and the launch of Stribild^® (elvitegravir 150
mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300
mg) in the third quarter of 2012. Product sales for the second quarter
increased 20 percent in the U.S. and 4 percent in Europe compared to the
second quarter of 2012.

Antiviral Product Sales

Antiviral product sales increased 15 percent to $2.31 billion for the second
quarter of 2013, up from $2.01 billion for the second quarter of 2012,
reflecting sales growth of 20 percent in the U.S. and 5 percent in Europe. The
increase reflects strong underlying demand for our new single tablet regimen
products, specifically Complera/Eviplera and Stribild.

                   Three Months Ended                   Six Months Ended            
                    June 30,                               June 30,
(In thousands,                                    %                                      %
except              2013          2012           Change   2013          2012           Change
percentages)
Antiviral product   $ 2,312,247    $ 2,012,283    15   %   $ 4,373,325    $ 3,938,089    11  %
sales
Atripla             938,108        904,023        4    %   1,815,181      1,791,619      1   %
Truvada             807,779        785,933        3    %   1,508,021      1,544,196      (2  )%
Viread              250,188        215,414        16   %   460,520        407,107        13  %
Complera/Eviplera   188,683        72,909         159  %   336,872        125,089        169 %
Stribild            99,394         —              —        191,542        —              —
                                                                                             

Cardiovascular Product Sales

Cardiovascular product sales increased 19 percent to $234.9 million for the
second quarter of 2013.

                Three Months Ended               Six Months Ended        
                 June 30,                           June 30,
(In thousands,                             %                                  %
except           2013        2012         Change   2013        2012         Change
percentages)
Cardiovascular   $ 234,854    $ 197,189    19  %    $ 449,247    $ 367,678    22  %
product sales
Letairis         128,257      101,634      26  %    246,364      188,922      30  %
Ranexa           106,597      95,555       12  %    202,883      178,756      13  %
                                                                                  

Operating Expenses and Other

Non-GAAP research and development (R&D) expenses increased due to Gilead's
continued investment in its product pipeline, particularly in liver disease
and oncology. Non-GAAP selling, general and administrative (SG&A) expenses
increased primarily due to the ongoing growth and expansion of Gilead's
business.

Interest expense decreased primarily due to the repayment of the convertible
senior notes due in May 2013 and bank debt issued in connection with the
acquisition of Pharmasset Inc. Gilead repaid debt totaling $929.6 million in
the first half of 2013 and $700.0 million in the same period of 2012.

                      Three Months Ended         Six Months Ended
                       June 30,                    June 30,
(In thousands,         2013         2012          2013          2012
except percentages)
Non-GAAP research
and development        $ 487,771     $ 371,398     $ 947,747      $ 702,736
expenses ^(1)
Non-GAAP selling,
general and            $ 376,336     $ 298,731     $ 709,400      $ 606,472
administrative
expenses ^(1)
                                                                  
Interest expense       $ (78,008 )   $ (88,418 )   $ (159,795 )   $ (185,688 )
                                                                             

^(1) Non-GAAP R&D expenses and SG&A expenses exclude the impact of
acquisition-related, restructuring and stock-based compensation expenses where
applicable.

Net Foreign Currency Exchange Impact

The net foreign currency exchange impact on second quarter 2013 product sales
and pre-tax earnings was unfavorable $21.0 million and $13.2 million,
respectively, compared to the second quarter of 2012.

Cash, Cash Equivalents and Marketable Securities

As of June30, 2013, Gilead had $2.98 billion of cash, cash equivalents and
marketable securities compared to $2.58 billion as of December31, 2012.
During the first half of 2013, Gilead generated $1.63 billion in operating
cash flow.

Product & Pipeline Updates Announced by Gilead During the Second Quarter of
2013 Include:

Antiviral Program

April:

  *Submission of a New Drug Application (NDA) to the U.S. Food and Drug
    Administration (FDA) for marketing approval to support the use of
    sofosbuvir and ribavirin (RBV) as an all-oral therapy for patients with
    genotype 2 and 3 chronic hepatitis C infection (HCV), and for sofosbuvir
    in combination with RBV and pegylated interferon (peg-IFN) for
    treatment-naïve patients with genotype 1, 4, 5 and 6 HCV infection. The
    FDA granted priority review for this filing in June and set a target
    review date of December 8, 2013 under the Prescription Drug User Fee Act.
  *Detailed results from four Phase 3 studies (NEUTRINO, FISSION, POSITRON
    and FUSION) evaluating sofosbuvir were presented at the annual meeting of
    the European Association for the Study of the Liver. The sofosbuvir NDA is
    supported primarily by data from these four Phase 3 studies. Sofosbuvir
    was administered to nearly 1,000 patients with HCV as part of an all-oral
    12-week or 16-week treatment regimen in combination with RBV in genotypes
    2 and 3, or with RBV and peg-IFN for 12 weeks in genotypes 1, 4, 5 and 6.

May:

  *Interim results from the Phase 2 LONESTAR study, which evaluated eight and
    12-week courses of therapy with the once-daily fixed-dose combination of
    sofosbuvir/ledipasvir with and without RBV in treatment-naïve,
    non-cirrhotic patients. In this study, 19/19 patients in the 12-week arm
    had a sustained virologic response four weeks after completing therapy
    (SVR4) and 40/41 patients in the eight-week arms had a sustained virologic
    response eight weeks after stopping therapy (SVR8), with one relapse
    occurring in the arm receiving sofosbuvir/ledipasvir without RBV. Two
    additional cohorts in the LONESTAR study evaluated a 12-week course of the
    fixed-dose combination of sofosbuvir/ledipasvir with or without RBV in
    patients who had previously failed therapy with an HCV-specific protease
    inhibitor-based regimen. Half of the treatment-experienced patients had
    documented, compensated cirrhosis. Ninety-five percent of patients in each
    arm achieved SVR4, one cirrhotic patient in the sofosbuvir/ledipasvir arm
    relapsed and one patient in the sofosbuvir/ledipasvir plus RBV arm was
    lost to follow-up.
  *Plans to initiate a third Phase 3 study (ION-3) of sofosbuvir/ledipasvir
    for the treatment of HCV, evaluating the once-daily fixed-dose combination
    of sofosbuvir/ledipasvir for eight weeks with and without RBV and for 12
    weeks without RBV in 600 non-cirrhotic, treatment-naïve genotype 1 HCV
    patients.
  *Submission of a Marketing Authorisation Application for sofosbuvir to the
    European Medicines Agency on April 17, 2013, which was fully validated and
    is under assessment.
  *Granting of marketing authorization by the European Commission for
    Stribild, a single tablet regimen for the treatment of HIV-1 infection in
    adults who are antiretroviral treatment-naïve or are infected with HIV-1
    without known mutations associated with resistance to any of the three
    antiretroviral agents in Stribild. This approval allows for the marketing
    of Stribild in all 27 countries of the European Union.

Oncology Program

May:

  *Results from a Phase 2 study (Study 101-08) evaluating idelalisib
    (formerly GS-1101) in combination with rituximab for older patients with
    treatment-naïve chronic lymphocytic leukemia. This regimen achieved a
    complete response rate of 19 percent and an overall response rate of 97
    percent, with estimated progression-free survival at 24 months of 93
    percent. These results were presented at the American Society of Clinical
    Oncology Annual Meeting.

June:

  *Interim results from a single-arm, open-label Phase 2 study (Study 101-09)
    evaluating idelalisib for the treatment of patients with indolent
    non-Hodgkin's lymphoma that is refractory (non-responsive) to rituximab
    and to alkylating-agent-containing chemotherapy. Single-agent treatment
    with idelalisib achieved an overall response rate of 53.6 percent, with a
    median duration of response at this interim analysis of 11.9 months.
    Detailed study results were presented at the International Conference on
    Malignant Lymphoma.

Conference Call

At 4:30 p.m. Eastern Time today, Gilead's management will host a conference
call and a simultaneous webcast to discuss results from its second quarter
2013 as well as provide a general business update. To access the webcast live
via the internet, please connect to the company's website at www.gilead.com 15
minutes prior to the conference call to ensure adequate time for any software
download that may be needed to hear the webcast. Alternatively, please call
1-866-730-5771 (U.S.) or 1-857-350-1595 (international) and dial the
participant passcode 26371472 to access the call.

A replay of the webcast will be archived on the company's website for one
year, and a phone replay will be available approximately two hours following
the call through July 28, 2013. To access the phone replay, please call
1-888-286-8010 (U.S.) or 1-617-801-6888 (international) and dial the
participant passcode 87549354.

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and
commercializes innovative therapeutics in areas of unmet medical need. The
company's mission is to advance the care of patients suffering from
life-threatening diseases worldwide. Headquartered in Foster City, California,
Gilead has operations in North America, Europe and Asia-Pacific.

Non-GAAP Financial Information

Gilead has presented certain financial information in accordance with U.S.
generally accepted accounting principles (GAAP) and also on a non-GAAP basis.
Management believes this non-GAAP information is useful for investors, when
considered in conjunction with Gilead's GAAP financial statements, because
management uses such information internally for its operating, budgeting and
financial planning purposes. Non-GAAP information is not prepared under a
comprehensive set of accounting rules and should only be used to supplement an
understanding of Gilead's operating results as reported under GAAP. A
reconciliation between GAAP and non-GAAP financial information is provided in
the table on pages 7 and 8.

Forward-looking Statements

Statements included in this press release that are not historical in nature
are forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Gilead cautions readers that forward-looking
statements are subject to certain risks and uncertainties that could cause
actual results to differ materially. These risks and uncertainties include:
Gilead's ability to achieve its anticipated full year 2013 financial results;
Gilead's ability to sustain growth in revenues for its antiviral,
cardiovascular and respiratory programs; availability of funding for state
AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP
purchases driven by federal and state grant cycles which may not mirror
patient demand and may cause fluctuations in Gilead's earnings; the
possibility of unfavorable results from clinical trials involving sofosbuvir,
the fixed-dose combination of sofosbuvir/ledipasvir and idelalisib; the levels
of inventory held by wholesalers and retailers which may cause fluctuations in
Gilead's earnings; Gilead's ability to submit NDAs for new product candidates
in the timelines currently anticipated, including the fixed-dose combination
of sofosbuvir/ledipasvir for the treatment of HCV; Gilead's ability to receive
regulatory approvals in a timely manner or at all, for new and current
products, including sofosbuvir for the treatment of HCV; Gilead's ability to
successfully commercialize its products, including Stribild; Gilead's ability
to successfully develop its respiratory, cardiovascular and
oncology/inflammation programs; safety and efficacy data from clinical studies
may not warrant further development of Gilead's product candidates, including
sofosbuvir, the fixed-dose combination of sofosbuvir/ledipasvir and
idelalisib; the potential for additional austerity measures in European
countries that may increase the amount of discount required on Gilead's
products; fluctuations in the foreign exchange rate of the U.S. dollar that
may cause an unfavorable foreign currency exchange impact on Gilead's future
revenues and pre-tax earnings; and other risks identified from time to time in
Gilead's reports filed with the U.S. Securities and Exchange Commission (SEC).
In addition, Gilead makes estimates and judgments that affect the reported
amounts of assets, liabilities, revenues and expenses and related disclosures.
Gilead bases its estimates on historical experience and on various other
market-specific and other relevant assumptions that it believes to be
reasonable under the circumstances, the results of which form the basis for
making judgments about the carrying values of assets and liabilities that are
not readily apparent from other sources. Actual results may differ
significantly from these estimates. You are urged to consider statements that
include the words may, will, would, could, should, might, believes, estimates,
projects, potential, expects, plans, anticipates, intends, continues,
forecast, designed, goal, or the negative of those words or other comparable
words to be uncertain and forward-looking. Gilead directs readers to its press
releases, Quarterly Report on Form 10-Q for the quarter ended March 31, 2013
and other subsequent disclosure documents filed with the SEC. Gilead claims
the protection of the Safe Harbor contained in the Private Securities
Litigation Reform Act of 1995 for forward-looking statements. All
forward-looking statements are based on information currently available to
Gilead, and Gilead assumes no obligation to update any such forward-looking
statements.

 Gilead owns or has rights to various trademarks, copyrights and trade names
 used in our business, including the following: GILEAD^®, GILEAD SCIENCES^®,
TRUVADA^®, VIREAD^®, HEPSERA^®, AMBISOME^®, EMTRIVA^®, COMPLERA^®, EVIPLERA^®,
          STRIBILD^®, VISTIDE^®, LETAIRIS^®, RANEXA^® and CAYSTON^®.

ATRIPLA^® is a registered trademark belonging to Bristol-Myers Squibb& Gilead
                                Sciences, LLC.

For more information on Gilead Sciences, Inc., please visit www.gilead.com or
call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).


GILEAD SCIENCES, INC.

CONSOLIDATED STATEMENTS OF INCOME

(unaudited)

(in thousands, except per share amounts)
                                              
                 Three Months Ended              Six Months Ended
                 June 30,                        June 30,
                 2013           2012            2013           2012
Revenues:
Product sales    $ 2,657,285     $ 2,321,240     $ 5,050,853     $ 4,529,582
Royalty,
contract and     110,109        83,946         248,176        158,053     
other revenues
Total revenues   2,767,394      2,405,186      5,299,029      4,687,635   
Costs and
expenses:
Cost of goods    684,663         617,345         1,319,111       1,198,276
sold
Research and     523,902         396,244         1,021,534       854,455
development
Selling,
general and      404,991        332,505        779,287        775,626     
administrative
Total costs      1,613,556      1,346,094      3,119,932      2,828,357   
and expenses
Income from      1,153,838       1,059,092       2,179,097       1,859,278
operations
Interest         (78,008     )   (88,418     )   (159,795    )   (185,688    )
expense
Other income     (231        )   (1,075      )   (3,555      )   (35,160     )
(expense), net
Income before
provision for    1,075,599       969,599         2,015,747       1,638,430
income taxes
Provision for    307,981        263,525        530,419        494,825     
income taxes
Net income       767,618         706,074         1,485,328       1,143,605
Net loss
attributable
to               4,987          5,490          9,463          9,915       
noncontrolling
interest
Net income
attributable     $ 772,605      $ 711,564      $ 1,494,791    $ 1,153,520 
to Gilead
Net income per
share
attributable
to Gilead        $ 0.51         $ 0.47         $ 0.98         $ 0.76      
common
stockholders -
basic
Net income per
share
attributable
to Gilead        $ 0.46         $ 0.46         $ 0.89         $ 0.74      
common
stockholders -
diluted
Shares used in
per share        1,526,945      1,513,902      1,524,174      1,513,238   
calculation -
basic
Shares used in
per share        1,694,577      1,561,012      1,683,269      1,558,492   
calculation -
diluted
                                                                             

GILEAD SCIENCES, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION

(unaudited)

(in thousands, except percentages and per share amounts)
                                                
                       Three Months Ended          Six Months Ended
                       June 30,                    June 30,
                       2013         2012          2013           2012
Cost of goods sold
reconciliation:
GAAP cost of goods     $ 684,663     $ 617,345     $ 1,319,111     $ 1,198,276
sold
Stock-based
compensation           (2,632    )   (2,119    )   (4,473      )   (4,220      )
expenses
Acquisition
related-amortization   (21,264   )   (15,836   )   (42,528     )   (31,672     )
of purchased
intangibles
Non-GAAP cost of       $ 660,767    $ 599,390    $ 1,272,110    $ 1,162,384 
goods sold
                                                                   
Product gross margin
reconciliation:
GAAP product gross     74.2      %   73.5      %   73.9        %   73.6        %
margin
Stock-based
compensation           0.1       %   0.1       %   0.1         %   0.1         %
expenses
Acquisition
related-amortization   0.8       %   0.7       %   0.8         %   0.7         %
of purchased
intangibles
Non-GAAP product       75.1      %   74.3      %   74.8        %   74.4        %
gross margin^(1)
                                                                   
Research and
development expenses
reconciliation:
GAAP research and      $ 523,902     $ 396,244     $ 1,021,534     $ 854,455
development expenses
Stock-based
compensation           (24,646   )   (20,355   )   (51,521     )   (138,978    )
expenses
Restructuring          (67       )   (1,576    )   (4,824      )   (7,090      )
expenses
Acquisition
related-transaction    —             (345      )   —               (345        )
costs
Acquisition
related-contingent     (11,418   )   (2,570    )   (17,442     )   (5,306      )
consideration
remeasurement
Non-GAAP research
and development        $ 487,771    $ 371,398    $ 947,747      $ 702,736   
expenses
                                                                   
Selling, general and
administrative
expenses
reconciliation:
GAAP selling,
general and            $ 404,991     $ 332,505     $ 779,287       $ 775,626
administrative
expenses
Stock-based
compensation           (28,675   )   (25,929   )   (61,726     )   (147,873    )
expenses
Restructuring          306           (7,251    )   (438        )   (10,407     )
expenses
Acquisition
related-transaction    (4        )   (594      )   (7,160      )   (10,874     )
costs
Acquisition
related-amortization   (282      )   —            (563        )   —           
of purchased
intangibles
Non-GAAP selling,
general and            $ 376,336    $ 298,731    $ 709,400      $ 606,472   
administrative
expenses
                                                                   
Operating margin
reconciliation:
GAAP operating         41.7      %   44.0      %   41.1        %   39.7        %
margin
Stock-based
compensation           2.0       %   2.0       %   2.2         %   6.2         %
expenses
Restructuring          0.0       %   0.4       %   0.1         %   0.4         %
expenses
Acquisition
related-transaction    0.0       %   0.0       %   0.1         %   0.2         %
costs
Acquisition
related-amortization   0.8       %   0.7       %   0.8         %   0.7         %
of purchased
intangibles
Acquisition
related-contingent     0.4       %   0.1       %   0.3         %   0.1         %
consideration
remeasurement
Non-GAAP operating     44.9      %   47.2      %   44.7        %   47.3        %
margin^(1)
                                                                   
Interest expense
reconciliation:
GAAP interest          $ (78,008 )   $ (88,418 )   $ (159,795  )   $ (185,688  )
expense
Acquisition
related-transaction    —            —            —              7,333       
costs
Non-GAAP interest      $ (78,008 )   $ (88,418 )   $ (159,795  )   $ (178,355  )
expense
                                                                   
Net income
attributable to
Gilead
reconciliation:
GAAP net income
attributable to        $ 772,605     $ 711,564     $ 1,494,791     $ 1,153,520
Gilead, net of tax
Stock-based
compensation           40,379        35,236        85,759          264,840
expenses
Restructuring          (244      )   6,426         5,124           12,772
expenses
Acquisition
related-transaction    4             651           7,160           13,542
costs
Acquisition
related-amortization   15,563        11,529        31,392          23,119
of purchased
intangibles
Acquisition
related-contingent     11,418       1,871        17,442         3,873       
consideration
remeasurement
Non-GAAP net income
attributable to        $ 839,725    $ 767,277    $ 1,641,668    $ 1,471,666 
Gilead, net of tax
                                                                   
                                                                   
                       Three Months Ended          Six Months Ended
                       June 30,                    June 30,
                       2013          2012          2013            2012
Diluted earnings per
share
reconciliation:
GAAP diluted           $ 0.46        $ 0.46        $ 0.89          $ 0.74
earnings per share
Stock-based
compensation           0.02          0.02          0.05            0.17
expenses
Restructuring          (0.00     )   0.00          0.00            0.01
expenses
Acquisition
related-transaction    0.00          0.00          0.00            0.01
costs
Acquisition
related-amortization   0.01          0.01          0.02            0.01
of purchased
intangibles
Acquisition
related-contingent     0.01         0.00         0.01           0.00        
consideration
remeasurement
Non-GAAP diluted
earnings per           $ 0.50       $ 0.49       $ 0.98         $ 0.95      
share^(1)
                                                                   
Shares used in per
share calculation
(diluted)
reconciliation:
GAAP shares used in
per share              1,694,577     1,561,012     1,683,269       1,558,492
calculation
(diluted)
Share impact of
current stock-based    (1,228    )   (3,146    )   (1,453      )   (3,342      )
compensation rules
Non-GAAP shares used
in per share           1,693,349    1,557,866    1,681,816      1,555,150   
calculation
(diluted)
                                                                   
Non-GAAP adjustment
summary:
Cost of goods sold     $ 23,896      $ 17,955      $ 47,001        $ 35,892
adjustments
Research and
development expenses   36,131        24,846        73,787          151,719
adjustments
Selling, general and
administrative         28,655        33,774        69,887          169,154
expenses adjustments
Interest expense       —            —            —              7,333       
adjustments
Total non-GAAP
adjustments before     88,682        76,575        190,675         364,098
tax
Income tax effect      (21,562   )   (20,862   )   (43,798     )   (45,952     )
Total non-GAAP
adjustments after      $ 67,120     $ 55,713     $ 146,877      $ 318,146   
tax
                                                                   
^(1) Amounts may not sum due to rounding.


GILEAD SCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)
                                                               
                                               June 30,   December 31,
                                               2013               2012^(1)
                                               (unaudited)
Cash, cash equivalents and marketable          $  2,975,798       $ 2,582,086
securities
Accounts receivable, net                       1,895,913          1,751,388
Inventories                                    1,935,147          1,744,982
Property, plant and equipment, net             1,135,993          1,100,259
Intangible assets, net                         12,056,002         11,736,393
Goodwill                                       1,188,157          1,060,919
Other assets                                   1,437,364         1,263,811
Total assets                                   $  22,624,374     $ 21,239,838
                                                                  
Current liabilities                            $  4,937,138       $ 4,270,020
Long-term liabilities                          6,343,852          7,418,949
Stockholders’ equity^(2)                       11,343,384        9,550,869
Total liabilities and stockholders’ equity     $  22,624,374     $ 21,239,838

^(1) Derived from the audited consolidated financial statements as of December
31, 2012.
^(2) As of June 30, 2013, there were 1,528,890 shares of common stock issued
and outstanding.


GILEAD SCIENCES, INC.

PRODUCT SALES SUMMARY

(unaudited)

(in thousands)
                                                
                   Three Months Ended              Six Months Ended
                   June 30,                        June 30,
                   2013           2012            2013           2012
Antiviral
products:
Atripla – U.S.     $ 611,330       $ 570,835       $ 1,165,156     $ 1,132,879
Atripla – Europe   270,780         280,125         548,995         550,821
Atripla – Other    55,998         53,063         101,030        107,919
International
                   938,108        904,023        1,815,181      1,791,619
                                                                   
Truvada – U.S.     415,541         393,013         723,402         766,339
Truvada – Europe   324,992         328,814         657,019         650,690
Truvada – Other    67,246         64,106         127,600        127,167
International
                   807,779        785,933        1,508,021      1,544,196
                                                                   
Viread – U.S.      113,965         102,112         196,593         183,768
Viread – Europe    88,042          84,108          176,248         168,993
Viread – Other     48,181         29,194         87,679         54,346
International
                   250,188        215,414        460,520        407,107
                                                                   
Complera /         120,187         65,004          223,484         113,643
Eviplera – U.S.
Complera /
Eviplera –         59,301          7,198           98,263          10,465
Europe
Complera /
Eviplera – Other   9,195          707            15,125         981
International
                   188,683        72,909         336,872        125,089
                                                                   
Stribild – U.S.    96,961          —               188,939         —
Stribild –         1,848           —               1,848           —
Europe
Stribild – Other   585            —              755            —
International
                   99,394         —              191,542        —
                                                                   
Hepsera – U.S.     9,871           8,172           22,821          20,981
Hepsera – Europe   9,268           15,420          20,491          29,385
Hepsera – Other    2,317          2,599          4,567          5,122
International
                   21,456         26,191         47,879         55,488
                                                                   
Emtriva – U.S.     4,768           4,770           9,297           8,863
Emtriva – Europe   1,584           1,741           3,335           3,552
Emtriva – Other    287            1,302          678            2,175
International
                   6,639          7,813          13,310         14,590
                                                                   
Total Antiviral    1,372,623       1,143,906       2,529,692       2,226,473
products – U.S.
Total Antiviral
products –         755,815         717,406         1,506,199       1,413,906
Europe
Total Antiviral
products – Other   183,809        150,971        337,434        297,710
International
                   2,312,247      2,012,283      4,373,325      3,938,089
                                                                   
Letairis           128,257         101,634         246,364         188,922
Ranexa             106,597         95,555          202,883         178,756
AmBisome           75,137          83,653          160,412         168,417
Other products     35,047         28,115         67,869         55,398
                   345,038        308,957        677,528        591,493
                                                                   
Total product      $ 2,657,285    $ 2,321,240    $ 5,050,853    $ 4,529,582
sales

Contact:

Gilead Sciences, Inc.
Investors
Robin Washington, 650-522-5688
Patrick O'Brien, 650-522-1936
Media
Amy Flood, 650-522-5643
 
Press spacebar to pause and continue. Press esc to stop.